Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD

Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment

(2008) T. Korff et al.   BLOOD

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells

(2008) C. Chen et al.   BLOOD

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease

(2008) Peter Valent   BRITISH JOURNAL OF HAEMATOLOGY

Chronic Myeloid Leukemia Stem Cells

(2008) Edward Kavalerchik et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA